Loading...
•
Sep 30, 2023
Surmodics Q4 2023 Earnings Report
Reported an increase in revenue and positive GAAP and non-GAAP EPS compared to the prior-year period.
Key Takeaways
Surmodics reported an 8% increase in total revenue to $28.0 million for the fourth quarter of fiscal year 2023, with GAAP EPS of $0.47 and non-GAAP EPS of $0.53. The company's revenue performance exceeded its guidance range, driven by contributions from both business segments. Surmodics is strategically positioned for future success with a portfolio of key product growth catalysts and a healthy balance sheet.
Total revenue increased by 8% year-over-year to $28.0 million.
GAAP diluted EPS was $0.47, compared to $(1.06) in the prior-year period.
Non-GAAP diluted EPS was $0.53, compared to $(0.26) in the prior-year period.
Launched Preside™ medical device coating technology.
Revenue by Segment
Forward Guidance
Surmodics expects fiscal 2024 total revenue to range from $116 million to $121 million, representing a decrease of (13)% to (9)% compared to fiscal 2023. The company expects fiscal 2024 GAAP diluted loss per share to range from $(1.55) to $(1.20). Non-GAAP diluted loss per share in fiscal 2024 is expected to range from $(1.32) to $(0.97).
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...